Trial · NCT00918333
Adverse events262
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 262
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Blood disorder | Blood and lymphatic system disorders | Phase I (Panobinostat + Everolimus) | 0 | 23 | 0 |
| other | Blood disorder | Blood and lymphatic system disorders | Phase II (Panobinostat + Everolimus) | 1 | 93 | 1 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Phase I (Panobinostat + Everolimus) | 22 | 23 | 167 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Phase II (Panobinostat + Everolimus) | 91 | 93 | 349 |
| other | Palpitations | Cardiac disorders | Phase I (Panobinostat + Everolimus) | 0 | 23 | 0 |
| other | Palpitations | Cardiac disorders | Phase II (Panobinostat + Everolimus) | 1 | 93 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Phase I (Panobinostat + Everolimus) | 0 | 23 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Phase II (Panobinostat + Everolimus) | 1 | 93 | 1 |
| other | Keratitis | Eye disorders | Phase I (Panobinostat + Everolimus) | 0 | 23 | 0 |
| other | Keratitis | Eye disorders | Phase II (Panobinostat + Everolimus) | 1 | 93 | 1 |
| other | Constipation | Gastrointestinal disorders | Phase I (Panobinostat + Everolimus) | 0 | 23 | 0 |
| other | Constipation | Gastrointestinal disorders | Phase II (Panobinostat + Everolimus) | 2 | 93 | 3 |
| other | Diarrhea | Gastrointestinal disorders | Phase I (Panobinostat + Everolimus) | 15 | 23 | 76 |
| other | Diarrhea | Gastrointestinal disorders | Phase II (Panobinostat + Everolimus) | 54 | 93 | 204 |
| other | Dry mouth | Gastrointestinal disorders | Phase I (Panobinostat + Everolimus) | 0 | 23 | 0 |
| other | Dry mouth | Gastrointestinal disorders | Phase II (Panobinostat + Everolimus) | 1 | 93 | 1 |
| other | Dyspepsia | Gastrointestinal disorders | Phase I (Panobinostat + Everolimus) | 0 | 23 | 0 |
| other | Dyspepsia | Gastrointestinal disorders | Phase II (Panobinostat + Everolimus) | 1 | 93 | 1 |
| other | Ear, nose and throat examination abnormal | Gastrointestinal disorders | Phase I (Panobinostat + Everolimus) | 16 | 23 | 71 |
| other | Ear, nose and throat examination abnormal | Gastrointestinal disorders | Phase II (Panobinostat + Everolimus) | 52 | 93 | 101 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00918333/events